Izvorni znanstveni članak

https://doi.org/10.24869/psyd.2023.500

THE EFFECT OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION AND PHARMACOTHERAPY ON SERUM PROTEIN S100B IN TREATMENT-RESISTANT DEPRESSION

Gulcin Elboga ; Assoc. Prof. - Gaziantep University, Faculty of Medicine, Department of Psychiatry, Gaziantep, Turkey
Bahadır Demir ; Assoc. Prof - Gaziantep University, Faculty of Medicine, Department of Psychiatry, Gaziantep, Turkey
Ufuk Gonultas ; MD - Gaziantep University, Faculty of Medicine, Department of Psychiatry, Gaziantep, Turkey
Sengul Kocamer Sahin ; Assoc. Prof - Gaziantep University, Faculty of Medicine, Department of Psychiatry, Gaziantep, Turkey
Irem Surme ; MD - Gaziantep University, Faculty of Medicine, Department of Psychiatry, Gaziantep, Turkey
Abdurrahman Altindag ; Prof. - Gaziantep University, Faculty of Medicine, Department of Psychiatry, Gaziantep, Turkey
Seyithan Taysı ; Prof.- Gaziantep University,Faculty of Medicine, Department of MedicalBiochemistry, Gaziantep, Turkey

Sažetak

Background: Transcranial magnetic stimulation (TMS) is considered an effective and fast option for treating patients with
major depressive disorder. With the increase in treatment options, the determination of biomarkers that predict which treatment will
benefit patients the most has been a matter of curiosity for researchers.
Subjects and Methods: In this study, we aimed to determine the changes in serum concentrations of S100B, a neurotrophic
factor thought to play a role in psychiatric disorders after repetitive TMS (rTMS) and anti-depressant drugs (AD) therapy in patients
with major depressive disorder(MDD).In this cohort study, rTMS was applied to the left dorsolateral prefrontal cortex(DLPFC) of
drug-resistant MDD patients, while another group of MDD patients was treated with AD for three weeks. Patients were evaluated by
psychometric tests and serum S100B concentration at baseline and following intervention. There was also a healthy control group in
which patients’ S100B values were compared at baseline.
Results:There is a population with a total of 48 participants.(16 healthy controls,16 anti-depressant treatment groups, 16 individuals
who received rTMS in addition to anti-depressant ) A total of 48 participants completed the study, and the S100B levels of the
rTMS group and the anti-depressant drug group were found to be significantly higher than the healthy control group. S100B values,
which were higher in the anti-depressant and rTMS groups compared to healthy controls, showed a significant reduction in group time
interaction (start and end of treatment).
Conclision: rTMS of DLPFC demonstrated an effective complementary treatment for treatment-resistant patients with MDD,
especially for patients with relatively high serum S100B concentrations.

Ključne riječi

Major depressive disorder; S100B; Transcranial magnetic stimulation; Neuroplasticity; Biomarker in psychiatric disorders

Hrčak ID:

311403

URI

https://hrcak.srce.hr/311403

Datum izdavanja:

9.11.2023.

Posjeta: 0 *